Press Releases
Company News
View Summary Medivation Announces Second Quarter 2012 Financial Results Teleconference on August 9, 2012
Aug 2, 2012
PDF 7.3 KB Add to Briefcase
View Summary Enzalutamide Granted Priority Review by U.S. FDA for the Potential Treatment of Castration-Resistant Prostate Cancer in Patients Previously Treated With Chemotherapy
Jul 24, 2012
PDF 11.1 KB Add to Briefcase
View Summary Astellas and Medivation Announce European Regulatory Submission for Enzalutamide for the Treatment of Men With Advanced Prostate Cancer Post-Chemotherapy
Jun 26, 2012
PDF 11.4 KB Add to Briefcase
View Summary Medivation and Astellas Provide Update on PREVAIL Enrollment
Jun 6, 2012
PDF 12.4 KB Add to Briefcase
View Summary Medivation and Astellas Announce Enzalutamide Data Relating to Quality of Life Measures and Extension of Time to First Skeletal-Related Event
Jun 2, 2012
PDF 12.5 KB Add to Briefcase
View Summary Medivation and Astellas Announce Initiation of Expanded Access Program for Enzalutamide (formerly MDV3100) in the United States
May 30, 2012
PDF 12.6 KB Add to Briefcase
View Summary Medivation and Astellas Announce Submission of New Drug Application for Enzalutamide for the Treatment of Castration-Resistant Prostate Cancer in Patients Previously Treated With Chemotherapy
May 21, 2012
PDF 11.8 KB Add to Briefcase
View Summary Medivation and Astellas Announce Enzalutamide (Formerly MDV3100) Data to Be Presented at ASCO Annual Meeting 2012
May 18, 2012
PDF 10.9 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conferences
May 11, 2012
PDF 8.0 KB Add to Briefcase
View Summary Medivation Reports First Quarter Financial Results and Provides Corporate Update
May 8, 2012
PDF 23.3 KB Add to Briefcase
View Summary Medivation Announces First Quarter 2012 Financial Results Teleconference on May 8, 2012
May 1, 2012
PDF 7.6 KB Add to Briefcase
View Summary Medivation Announces Poster Presentations at AACR Annual Meeting 2012
Mar 30, 2012
PDF 8.2 KB Add to Briefcase
View Summary Medivation, Inc. Closes 2.625% Convertible Senior Notes Due 2017
Mar 19, 2012
PDF 10.7 KB Add to Briefcase
View Summary Medivation, Inc. Prices $225 Million 2.625% Convertible Senior Notes Due 2017
Mar 13, 2012
PDF 11.4 KB Add to Briefcase
View Summary Medivation, Inc. to Offer $175 Million Convertible Senior Notes Due 2017
Mar 12, 2012
PDF 10.9 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conferences
Mar 2, 2012
PDF 7.8 KB Add to Briefcase
View Summary Medivation Reports Fourth Quarter and Year-End 2011 Financial Results and Provides Corporate Update
Feb 29, 2012
PDF 21.4 KB Add to Briefcase
View Summary Medivation Announces Fourth Quarter and Year-End Financial Results Teleconference on February 29, 2012
Feb 22, 2012
PDF 7.8 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conferences
Feb 10, 2012
PDF 7.9 KB Add to Briefcase
View Summary Medivation and Astellas Announce Positive Results From the Phase 3 AFFIRM Trial of MDV3100 in Prostate Cancer Patients Who Received Prior Chemotherapy
Jan 31, 2012
PDF 15.3 KB Add to Briefcase
Showing 81-100 of 311 Page: 1 2 3 4 5 6 7 8 9 ... 16  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

Top